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Backround: Right lobe donations are known to expose the donors to more surgical risks than left lobe
donations. In the present study, the effects of remnant volume on donor outcomes after right lobe living
donor hepatectomies were investigated.
Methods: The data on 262 consecutive living liver donors who had undergone a right hepatectomy from
January 2004 to June 2011 were retrospectively analysed. The influence of the remnant on the outcomes
was investigated according to the two different definitions. These were: (i) the ratio of the remnant liver
volume to total liver volume (RLV/TLV) and (ii) the remnant liver volume to donor body weight ratio
(RLV/BWR). For RLV/TLV, the effects of having a percentage of 30% or below and for RLV/BWR, the
effects of values lower than 0.6 on the results were investigated.
Results: Complication and major complication rates were 44.7% and 13.2% for donors with RLV/TLV
of 30%, and 35.9% and 9.4% for donors with RLV/BWR of < 0.6, respectively. In donors with
RLV/TLV of 30%, RLV/BWR being below or above 0.6 did not influence the results in terms of liver
function tests, complications and hospital stay. The main impact on the outcome was posed by RLV/
TLV of 30%.
Conclusion: Remnant volume in a right lobe living donor hepatectomy has adverse effects on donor
outcomes when RLV/TLV is 30% independent from the rate of RLV/BWR with a cut-off point of 0.6.
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Introduction
Liver transplantation is a well-established and widely used treat-
ment method for end-stage liver disease. In countries where cadav-
eric organ supply is problematic, living donor liver transplantation
is prioritized. During this process, small-for-size syndrome expe-
rienced in left lobe grafts results in more frequent use of right lobe
donations.1 For right lobe donations, donor morbidity is reported
to be 0–67% whereas the main drawback is the percentage of donor
remnant.2–8 In most human beings, right lobe volume is 45–80% of
the total liver volume; left lobe volume on the other hand is 15–45%
of the total volume.9 In general, remnant liver volume after right
hepatectomies is known to be around 20–40%2,10,11 Together with
increasing experience and graft needs, transplant centres are
guided towards using donors with smaller remnant volumes, i.e.
<30% total liver volume, that qualify as marginal.2 In previous
studies, remnant volume was expressed as the percentage of the
remnant volume to the total liver volume. To the best of our
knowledge, the present study is the first to evaluate donor morbid-
ity after living donor right lobe donation based on the remnant
liver volume to donor body weight ratio.
Whether remnant liver volume (RLV) to donor body weight
ratio (BWR) (RLV/BWR) had any impact on outcome of the
donors in addition to the widely used RLV to total liver volume
(TLV) ratio (RLV/TLV) by the transplant centres was assessed
which is generally accepted to be 30%.
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Patients and methods
From January 2004 to June 2011, 262 consecutive living liver
donors who had undergone a right hepatectomy at Florence
Nightingale Hospital Organ Transplant Center were included in
the study. In the present study, the remnant liver after a right lobe
living donor hepatectomy was expressed both as the percentage of
total liver volume (RLV/TLV) and as a ratio of donor body weight
(RLV/BWR) and the effects of both on donor postoperative out-
comes were investigated. Cut-off points were determined by
receiver-operating curve (ROC) analysis. For RLV/TLV, 30% and
below, and for RLV/BWR the value of under 0.6 were assigned as
cut-off points. Donors were studied for age, gender, aspartate
transaminase (AST), alanine transaminase (ALT), total bilirubin
and international normalized ration (INR) levels, and complica-
tions within the first 7 post-operative days.
In order to assess the effects of the copresence of both instances
on the results, the donors were divided into four subgroups: A
(RLV/TLV 30% and RLV/BWR < 0.6), B (RLV/TLV 30% and
RLV/BWR  0.6), C (RLV/TLV > 30% and RLV/BWR < 0.6) and
D (RLV/TLV > 30% and RLV/BWR  0.6).
Remnant and total liver volume measurements were performed
with multidetector computed tomography (CT). Operative details
were published elsewhere.12 Minor and major complications were
categorized according to the modified Clavien’s classification.3
The problems in Clavien 1 and 2, which resolved without invasive
interventions, were accepted as minor complications. The prob-
lems in Clavien 3 and 4 that required radiological, endoscopic or
surgical interventions were accepted as major complications. A
post-operative total bilirubin level of >5 mg/dl was accepted as
hyperbilirubinemia.
CT protocol and volume calculation
Multidetector computed tomography (MDCT) was performed on
a 16-slice CT scanner (Sensation 16; Siemens Medical Solutions,
Erlangen, Germany) using a three-phase contrast-enhanced pro-
tocol with a 1.0 mm slice thickness. For volumetric assessment,
the hepatic venous phase was used with reconstructions of 5 mm
thickness. Volumes were calculated using a software package
(StereoInvestigator, version 6.0; Microbrightfield, Colchester, VT,
USA) that uses a point counting technique based on the Cavalieri
principle. Large vessels such as the extrahepatic portal vein in the
area of the porta hepatis and the inferior vena cava, as well as
larger fissures, and the teres hepatic ligament were excluded from
volumetric markings. MDCT measurements were conducted on
the middle hepatic vein (MHV) with the marking line passing
5 mm lateral (towards right lobe) to the MHV thereby leaving
MHV on the remnant.
Donor evaluation
Individuals between 18–65 years of age who did not have any
health problems and who were relatives of the recipients until
fourth degree were accepted as donor candidates.
Donor candidates were checked for ABO blood group match,
biochemical analyses, a viral hepatitis profile, factor 5 and pro-
thrombin gene mutations. Examinations were carried out by a
team consisting of a hepatologist, a transplant surgeon and a
psychiatrist. Donor candidates who were found acceptable were
evaluated with an abdominal ultrasound. Donor candidates
having liver steatosis of more than 10% in radiological evaluation,
a body mass index of > 30 and anti-HBc positivity underwent
routine liver biopsy. Candidates who were found to be eligible
were assessed with volumetric computerized tomography and
CT angiography. Bile duct anatomy was assessed with MR
cholangiography.
In the first 100 live donor liver transplantations, as the deceased
donor option was very limited, and when the recipients did not
have any other live donor candidates, individuals with calculated
remnant volumes of less than 30% were occasionally accepted for
donations. After publishing the results of those data suggesting
higher complication rates with remnant volumes < 30%, donors
with < 30% remnant volumes were not accepted; however, donors
with 30% remnant volumes continue to be accepted.13 With this
limit of 30% in mind, the effects of RLV/BWR with different
cut-off points, if any, on the post-operative course and complica-
tions in donors in addition to RLV/TLV of 30% were assessed.
Statistical analysis
Values of measured variables were expressed as means standard
deviation or as ranges. Categorical variables were expressed as
frequencies and percentages. For statistical analysis, continuous
parameters in each group were compared using an independent
sample t-test, and categorical parameters were compared with the
chi-square test. ROC curve analysis was used to determine sensi-
tivity and specificity of the values for RLV/TLV, RLV/BWR and
hyperbilirubinemia. The differences between continuous vari-
ables in subgroups were assessed using the anova test. Tukey’s
test or Tamhanes’s T2 test was used according to the variances of
the groups. As group 4 had a much greater sample size compared
with the other groups, the Welch statistic was used to assess the
differences.
All analyses were performed with SPSS 16.0 for Windows
(SPSS, Chicago, IL); a value of P < 0.05 was considered significant.
Results
Donor’s charasteristic features and post-operative outcome
according to the RLV/TLV and RLV/BWR rates are shown in
Table 1.
Mean radiological measurement of the grafts and mean actual
graft weight were 900  184 g and 880  168 g; radiologically
measured weight and actual weight of the grafts were significantly
correlated (r = 0.75, P = 0.0001). The mean radiological/actual
graft weight was 1019. Radiological/actual graft weight ratios were
1.04 and 0.98 in patients with grafts with MHV (n = 77) and
without MHV (n = 184) (P = 0.01).
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The number and types of post-operative complications are
shown in Tables 1 and 2, respectively.
In donors with RLV/TLV 30%, day 7 and peak total bilirubin
levels, day 7 AST and peak INR values, and the number of com-
plications were statistically significantly higher compared with
donors with RLV/TLV > 30%.
Donors with RLV/BWR < 0.6 had significantly higher values for
day 7 and peak total bilirubin, day 7 INR, peak ALT and hospital
stay compared with donors with RLV/BWR 0.6. Post-operative
INR and bilirubin levels according to RLV/TLV and RLV/BWR
rates are demonstrated in Figs 1–4, respectively.
In the ROC curve analysis, having a RLV/BWR of less than 0.6
predicted major complications and hyperbilirubinemia with a
sensitivity of 70% and a specificity of 76% (area under curve 0.47,
P > 0.05). Having a RVL/TLV of 30% or below predicted major
complications with a sensitivity of 90% and specificity of 93%
(area under the curve 0.60, P < 0.05), whereas it predicted hyper-
bilirubinemia with a sensitivity of 84% and a specificity of 96%
(area under curve 0.58, P < 0.05).
The post-operative course of donors according to the sub-
groups are shown in Table 3.
Donors with a RLV/TLV  30% (with or without RLV/BWR <
0.6) had significantly higher rates of hyperbilirubinemia. In
donors with a RLV/TLV of 30%, having a RLV/BWR of 0.6 and
above or below did not influence the results.
Bilirubin levels on days 3 (P = 0.03), 5 (P = 0.02) and 7 (P =
0.004), and peak INR (P = 0.01 and INR day 3 (P = 0.0001) levels










Age 38.8  10.5 36.1  10.4 NS 39.2  11 35.6  10 NS
Gender (M/F) 23/15 127/97 NS 36/28 114/84 NS
BMI 25.9  4 25.1  3.4 NS 26.1  3.6 24.6  3.2 NS
# of grafts with MHV/without MHV 9/29 68/156 NS 19/45 58/140 NS
RLV/BWR 0.61  0.22 0.73  0.22 0.003 0.54  0.19 0.77  0.2 0.000
RLV/TLV (%) 29.2  1.0 35.8  3.3 0.000 31.8  2.8 35.8  3.7 0.000
ALT (IU/L) Day 7 65  26 80  45 NS 78  37 78  45 NS
Peak 260  191 229  124 NS 263  171 224  121 0.047
AST (IU/L) Day 7 44  15.3 53.8  24 0.03 52  22 52  24 NS
Peak 234  177 201  102 NS 228  152 198  101 NS
INR Day 7 1.2  0.2 1.1  0.1 NS 1.2  0.18 1.1  0.18 0.036
Peak 1.91  0.2 1.73  0.26 0.000 1.8  0.25 1.7  0.26 NS
Bilirubin (mg/dl) Day 7 3.1  2.6 1.6  1.5 0.000 2.5  2.7 1.6  1.2 0.002
Peak 5.1  2.8 3.9  2.2 0.002 4.7  2.9 3.9  2 0.016
Hospital stay (day) 9.8  3.5 9  4.7 NS 10.9  7.9 8.5  2.5 0.000
No. of complications 17 61 0.029 23 55 NS
No. of major complications 5 15 NS 6 14 NS
Data were expressed mean  standard deviation.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; F, female; INR, international normalized ratio; M, male;
MHV, middle hepatic vein; Peak, highest value in the postoperative 7 days; POD, post-operative day. NS, not significant; RLV/BWR, remnant to body
weight ratio; RLV/TLV, remnant to total liver volume.











Minor wound infection 5 6
Fever 4 4
Mild pleural effusion 2 3
Biliary leak resolving spontaneously – 2
Parenteral nutrition – 2
Abdominal collection 3 3








Biliary leak/ERCP, sphincterotomy or
stent placement
1 1
Biliary leak/re-operation – 1
Intra-abdominal bleeding/re-operation 2 1
RLV/BWR, remnant to body weight ratio; RLV/TLV, remnant to total liver
volume; ERCP, endoscopic retrograde cholangiopancreatography.
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in Group A were significantly higher than Group D. Bilirubin
levels on days 5 (P = 0.005), 7 (P = 0.01) and peak INR (P = 0.01),
and INR day 3 (P = 0.0001) levels in Group B were significantly
higher than in Group D (P-values are given according to Tukey’s
or Tamhane’s test where appropriate).
To include the middle hepatic vein in the graft had no signifi-
cant effect in either case, with the cut-off points of 30% and 0.6 of
RLV/TLV and RLV/BWR, respectively (Tables 1 and 3). The length
of hospital stay was significantly increased by RLV/BWR < 0.6
(Table 1); however, when assessed together with RLV/TLV ( or
>30%), its effect dissapeared (Table 3).
Discussion
In living donor liver transplantations, to avoid small-for-size syn-
drome and insufficient graft function, the minimum value of graft
to recipient body weight ratio is generally accepted to be 0.8 or
above.5 However, in emergency transplantations, lower ratios such
as 0.6 have been used successfuly. In previous studies conducted
on donor morbidity, the main points of discussion were MHV
harvesting, age, steatosis and per cent remnant volume.12–18 The
effects of volume calculation based on body weight in donors as is
the case for the recipient were not analyzed. That is why we
approached remnant volume from two perspectives, namely the
ratio of remnant liver volume to total liver volume and the ratio of
remnant liver weight to total body weight of the donors.
The key to donor safety is to ensure the presence of sufficient
well functioning remnant liver volume. In previous studies per-
formed on normal livers after a hepatectomy, a remnant volume of
at least 27% was mentioned as being safe for the prevention of
liver failure.2,19–21 Remnant volumes at or above 30% for donor
safety should be maintained.
Small-for-size syndrome might develop as a result of small
remnants after major hepatectomies, and lead to liver dysfunction
characterized by lengthened cholestasis and coagulation disor-
ders.22 After major hepatectomies, increased portal hypertension
caused by transient sinusoidal narrowing and parenchymal loss
gives rise to deterioration of parenchymal functions, furthermore
damages in sinusoidal endothelial cells and Kupfer cells result in
the secretion of inflammatory cytokines.23–26
In the past, knowledge of the effects of remnant volume on
outcome was based on resections owing to tumours and on
experimental studies. Together with the widespread utilization of
living donor liver transplantation worldwide, increasing experi-
ence on donor hepatectomy resulted in a better understanding of
the issue. It should be kept in mind that, in resections performed
for tumours, most of the excised mass is non-functional, there is
no healthy liver tissue and the other lobe might develop contralat-
RLV    30%
RLV    30%
Figure 1 Post-operative international normalized ratio (INR) levels of
donors according to the remnant liver volume (RLV)
Figure 2 Post-operative bilirubin levels of donors according to the
remnant liver volume (RLV)
Figure 3 Post-operative international normalized ratio (INR) levels of
donors according to the remnant liver volume to donor body weight
ratio (RLV/BWR)
Figure 4 Post-operative bilirubin levels of donors according to the
remnant liver volume to donor body weight ratio (RLV/BWR)
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eral hypertrophy. On the contrary, in donor hepatectomy proce-
dures, totally healthy liver volumes are being lost. Taking into
consideration that volumetric CT measurements have a deviation
rate of 13% to 20%,27–29 ensurement of sufficient remnant volume
that would not put the donor under risk becomes increasingly
important.
Fatty liver is more prone to injuries by anaesthesia, ischaemia or
reperfusion damage.30,31 For this reason, in donors with steatosis,
calculation of remnant liver volume becomes more important. No
candidates with steatosis of 10% or more as donors were accepted.
As a result, hepatosteatosis did not become a factor that influenced
remnant liver volume and associated results.
In a previous study, RLV/BWR was expressed as being more
specific in predicting post-operative liver function in liver
resections.32 A different study by Chun et al.33 identified cut-off
values of RLV/TLV of 20% and RLV/BWR of 0.4 for hepatic
dysfunction. The same study found that patients with RLV/BWR
ratios of 0.4–0.5 and RLV/TLV of 20–25% were more prone to
hepatic dysfuntion. As leaving these remnant rates would not be
realistic in clinical practice for the safety of the living donors,
the values of 30% for RLV/TLV and 0.6 for RLV/BWR were
assessed.
When the present results were analyzed, both donors with a
RLV/TLV of  30% and with a RLV/BWR of < 0.6 had signifi-
cant deteriorations in their post-operative courses. Donors with
RLV/TLV of  30% had complication and major complication
rates of 44.7% and 13.2%, whereas these values were 35.9%
and 9.4% for donors with RLV/BWR of < 0.6. Complication and
major complication rates of the whole series were 29.7% and
7.6%, respectively.
In donors who had a RLV/TLV of  30%, having a RLV/BWR
of <0.6 or 0.6 did not influence the results in terms of hyperbi-
lirubinemia and complications. All the statistical differences con-
cerning post-operative bilirubin and INR levels appeared in
donors having a RLV/TLV of 30%. The real impact on the
outcome was created by a RLV/TLV of 30%. As an exception,
only those donors who had both a RLV/TLV of 30% and a
RLV/BWR of < 0.6 had higher complication rates of 52.2%.
However, this difference was not of statistical significance. More-
over, problems such as a pleural effusion, atelectasis and wound
infections that constitute most of the postoperative complications
may not be directly related to the donor remnant liver. However,
in donors with small remnant volumes, as has been shown by
several previous studies, the post-operative process is more diffi-
cult and these donors had longer hospital stays.
Likewise, the age of the donor and MHV harvesting are two
other parameters whose effects have been shown both on compli-
cations and post-operative liver function tests. The previous
studies have demonstrated that live donors above the age of 50
years had increases in the incidence of major complications.14 In
the present study, inclusion of MHV and age had no significant
effect on outcome.
Table 3 Post-operative course of donors according to the subgroups of different combinations of RLV/TLV and RLV/BWR
Group A Group B Group C Group D P
RLV/TLV  30%
plus RLV/BWR
< 0.6 (n = 23)
RLV/TLV  30%
plus RLV/BWR
 0.6 (n = 15)
RLV/TLV > 30%
plus RLV/BWR
< 0.6 (n = 41)
RLV/TLV > 30%
plus RLV/BWR
 0.6 (n = 183)
Mean age 38.4  10.6 39.5  10.8 39.6  11.3 37.3  10 NS
Hyperbilirubinemia n (%) 10 (43.5) 7 (46.7) 10 (24.4) 39 (21.3) 0.026
Right-lobe graft with MHV, n (%) 7 (30.4) 2 (13.3) 12 (29.3) 56 (30.6) NS
Mean hospital stay (day) 10.4  4.3 8.8  1.4 10  9.4 8.5  2.6 NS
Complications n (%) 12 (52.2) 5 (33.3) 11 (26.8) 50 (27.3) NS
Major complications n (%) 3 (13%) 2 (13.3) 3 (7.3) 12 (6.6) NS
Bilirubin day1 mg/dl (mean  SD) 2.8  2.0 2.9  1.1 2.6  1.5 2.7  1.5 NS
Bilirubin day3 mg/dl (mean  SD) 4.4  3.3 4.5  2.2 3.4  1.9 3.0  1.8 0.006
Bilirubin day5 mg/dl (mean  SD) 3.5  2.8 4.0  2.3 3.1  2.6 2.3  1.5 0.00
Bilirubin day7 mg/dl (mean  SD) 3.0  2.8 3.2  2.2 2.2  2.6 1.4  1.0 0.00
Bilirubin peak mg/dl (mean  SD) 5.0  2.9 5.4  2.5 4.5  3.0 3.8  1.9 0.005
INR day1 1.5  0.2 1.7  0.2 1.4  0.2 1.5  0.2 NS
INR day3 1.7  0.1 1.8  0.3 1.5  0.2 1.4  0.2 0.00
INR day5 1.4  0.1 1.4  0.1 1.4  0.3 1.3  0.1 NS
INR day7 1.2  0.2 1.2  0.1 1.2  0.1 1.1  0.1 NS
INR peak 1.9  0.2 1.9  0.2 1.7  0.2 1.7  0.2 0.002
P-values are the results of the one-way ANOVA test. The significance of differences among the groups (Tukey's or Tamhane's test, where applicable)
are expressed in the text.
RLV/BWR, remnant to body weight ratio; RLV/TLV, remnant to total liver volume; SD, standard deviation.
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In conclusion, having a remnant liver volume to total liver
volume percentage of equal or lower than 30% as well as a
remnant to body weight ratio of less than 0.6 have adverse effects
on post-operative liver function tests and complications after live
donor hepatectomies when taken into account separately.
However, when the two parameters of RLV/TLV and RLV/BWR
are combined, it is shown in the present study that the cut-off
point of remnant to body weight ratio of 0.6 has no significant
effect on post-operative course, a RLV/TLV of  30% is, by itself,
a significant indicator of increased complications and a more
difficult post-operative course.
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